TESARO Inc  

(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for Timothy Pearson�
27.82
-0.88 (-3.07%)
Oct 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.43 - 30.11
52 week 22.15 - 40.99
Open 29.49
Vol / Avg. 529,876.00/453,731.00
Mkt cap 1.03B
P/E     -
Div/yield     -
EPS -4.06
Shares 36.04M
Beta     -
Inst. own 100%
Nov 5, 2014
Q3 2014 TESARO Inc Earnings Call - 4:15PM EST - Add to calendar
Nov 5, 2014
Q3 2014 TESARO Inc Earnings Release - 4:00PM EST - Add to calendar
Sep 9, 2014
TESARO Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
TESARO Inc at Robert W. Baird & Co. Inc Health Care Conference
Sep 3, 2014
TESARO Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -86.83% -70.25%
Return on average equity -96.58% -77.35%
Employees 62 -
CDP Score - -

Address

SUITE 3300, 1000 WINTER STREET
WALTHAM, MA 02451
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 51
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Lawrence M. Alleva Independent Director
Age: 64
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Earl M. Collier Jr., Esq. Independent Director
Age: 65
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters